Ralf U Trappe

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi request reprint Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection
    R Trappe
    Department of Hematology and Oncology, Charite University Hospital Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transpl Infect Dis 9:42-5. 2007
  2. ncbi request reprint Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Ralf Trappe
    1Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Transplantation 83:912-8. 2007
  3. doi request reprint Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
    Ralf U Trappe
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 84:1708-12. 2007
  4. doi request reprint Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression
    R Trappe
    Department of Hematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 9:2331-7. 2009
  5. doi request reprint Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era
    Tulio E F Pfiffer
    1Department of Hematology, Oncology and Tumor Immunology, Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Tumori 97:436-41. 2011
  6. doi request reprint Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO)
    C Fotopoulou
    Department of Gynecology and Obstetrics, Charite, University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Thromb Res 124:531-5. 2009
  7. ncbi request reprint Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
    Ralf U Trappe
    Ralf U Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie Krankenhaus Bremen, Bremen University Medical Centre Schleswig Holstein, Kiel Ralf U Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charite Universitatsmedizin Berlin, Berlin Martin H Dreyling and Marion Subklewe, University of Munich, Munich Ulrich Dührsen and Andreas Hüttmann, University of Duisburg Essen, Essen Volker Kliem, Nephrological Centre Lower Saxony, Hann Münden Ingeborg A Hauser, J W Goethe University Hospital, Frankfurt, Germany Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven Eric Van Den Neste, Cliniques Universitaires Saint Luc, Brussels, Belgium Franck Morschhauser, Hopital Claude Huriez, Lille Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre Bénite Veronique Leblond and Sylvain Choquet, Universite Pierre et Marie Curie, Paris, France Peter Mollee, University of Queensland, Brisbane, Queensland, Germany
    J Clin Oncol . 2016

Detail Information

Publications7

  1. ncbi request reprint Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection
    R Trappe
    Department of Hematology and Oncology, Charite University Hospital Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transpl Infect Dis 9:42-5. 2007
    ....
  2. ncbi request reprint Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Ralf Trappe
    1Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Transplantation 83:912-8. 2007
    ..This retrospective analysis was undertaken to determine the efficacy and safety of salvage therapy in recipients of solid organ transplants with progression of PTLD after rituximab first-line therapy...
  3. doi request reprint Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab
    Ralf U Trappe
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Transplantation 84:1708-12. 2007
    ..Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity...
  4. doi request reprint Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression
    R Trappe
    Department of Hematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Am J Transplant 9:2331-7. 2009
    ..The immunosuppressive effect of single agent rituximab may partially compensate the negative impact of IR on the graft function. Thus, it is possible to reduce immunosuppression when using chemotherapy to treat PTLD...
  5. doi request reprint Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era
    Tulio E F Pfiffer
    1Department of Hematology, Oncology and Tumor Immunology, Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Tumori 97:436-41. 2011
    ..A growing number of patients with hepatocellular carcinoma undergo liver transplantation, but there is little data on recurrence and its treatment in the posttransplant setting...
  6. doi request reprint Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO)
    C Fotopoulou
    Department of Gynecology and Obstetrics, Charite, University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Thromb Res 124:531-5. 2009
    ..Venous thromboembolism (VTE) seems to have a negative prognostic impact in patients with solid tumors including primary ovarian cancer in many series. Only limited contemporary data exist regarding the impact of VTE on ROC...
  7. ncbi request reprint Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
    Ralf U Trappe
    Ralf U Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie Krankenhaus Bremen, Bremen University Medical Centre Schleswig Holstein, Kiel Ralf U Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charite Universitatsmedizin Berlin, Berlin Martin H Dreyling and Marion Subklewe, University of Munich, Munich Ulrich Dührsen and Andreas Hüttmann, University of Duisburg Essen, Essen Volker Kliem, Nephrological Centre Lower Saxony, Hann Münden Ingeborg A Hauser, J W Goethe University Hospital, Frankfurt, Germany Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven Eric Van Den Neste, Cliniques Universitaires Saint Luc, Brussels, Belgium Franck Morschhauser, Hopital Claude Huriez, Lille Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre Bénite Veronique Leblond and Sylvain Choquet, Universite Pierre et Marie Curie, Paris, France Peter Mollee, University of Queensland, Brisbane, Queensland, Germany
    J Clin Oncol . 2016
    ..Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective...